Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18948449 | USE OF ERGOTHIONEINE TO SUPPRESS DELETERIOUS EFFECTS OF SENESCENCE | November 2024 | January 2026 | Abandon | 14 | 2 | 0 | Yes | No |
| 18908587 | COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAME | October 2024 | July 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18907258 | S-BETA-HYDROXYBUTYRIC ACID COMPOSITIONS AND METHODS FOR DELIVERY OF KETONE BODIES | October 2024 | September 2025 | Allow | 12 | 2 | 0 | No | No |
| 18888371 | SOLID PSILOCIN SALTS | September 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18796446 | Methods for Preventing Ectopic Brain Mineralization in Alzheimer's Disease and Dementias | August 2024 | November 2025 | Abandon | 16 | 2 | 1 | No | No |
| 18663460 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | May 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18601445 | 5-BROMO-2-HYDROXY-N'-[(1E)-1-(PYRIDIN-2-YL) ETHYLIDENE]BENZOHYDRAZIDE AS AN ANTI-CANCER AND ANTIMICROBIAL AGENT | March 2024 | May 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18594323 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18594233 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | March 2024 | October 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18431308 | POTENTIATION OF HELMINTH TREATMENT | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18406539 | TOPICAL FORMULATIONS OF CHLOROPROCAINE AND METHODS OF USING SAME | January 2024 | September 2025 | Abandon | 20 | 2 | 0 | Yes | No |
| 18403360 | STERICALLY STABILIZED CARRIER COMPOSITIONS FOR TREATING A MAMMAL | January 2024 | November 2024 | Allow | 11 | 0 | 1 | No | No |
| 18402538 | 6-[4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | October 2024 | Allow | 10 | 3 | 0 | No | No |
| 18398480 | 4-[4,4-BIS(4-BROMOPHENYL)-5-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | December 2023 | October 2024 | Allow | 10 | 3 | 0 | No | No |
| 18515734 | TREATING PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18495012 | NICOTINE FORMULATION | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18481787 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18376339 | INJECTABLE IBUPROFEN FORMULATION | October 2023 | May 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18474108 | IMMUNOREGULATORY MICROPARTICLES FOR MODULATING INFLAMMATORY ARTHRITIDES | September 2023 | September 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18457567 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18364796 | THERAPY OF POST-OPERATIVE EMESIS WITH AMISULPRIDE | August 2023 | September 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18362028 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | July 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18223177 | DEUTERATED DERIVATIVES OF PSILOCYBIN AND USES THEREOF | July 2023 | August 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18349221 | ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION | July 2023 | April 2025 | Allow | 21 | 3 | 0 | No | No |
| 18325919 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | May 2023 | August 2024 | Allow | 14 | 2 | 0 | No | No |
| 18141170 | TREPROSTINIL PRODRUGS | April 2023 | November 2025 | Abandon | 31 | 2 | 0 | No | Yes |
| 18305589 | PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA | April 2023 | September 2025 | Abandon | 29 | 2 | 0 | No | No |
| 18302713 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | April 2023 | December 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18181228 | PREVENTIVE TREATMENT OF MIGRAINE | March 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18095877 | COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | January 2023 | February 2025 | Abandon | 25 | 2 | 0 | Yes | No |
| 18093774 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | January 2023 | October 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 18063486 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | December 2022 | January 2026 | Abandon | 38 | 4 | 0 | No | No |
| 18059806 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | November 2022 | July 2024 | Allow | 20 | 2 | 0 | No | No |
| 17989298 | COLLAGEN-BASED DEVICE HAVING ANTIFUNGAL PROPERTIES | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | Yes |
| 18049508 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | October 2022 | March 2025 | Allow | 29 | 4 | 0 | Yes | No |
| 17950802 | METHODS OF TREATING OCULAR INFLAMMATORY DISEASES | September 2022 | November 2024 | Allow | 26 | 3 | 0 | Yes | No |
| 17849803 | LIQUID COMPOSITIONS COMPRISING TERPENES AND CANNABINOIDS | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17780936 | PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING FIBROSIS, COMPRISING PHEOPHORBIDE COMPOUND AS ACTIVE INGREDIENT | May 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17779730 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS IN HUMANS | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17745126 | GPR40 AGONISTS | May 2022 | December 2024 | Allow | 31 | 5 | 1 | No | No |
| 17774051 | INHIBITOR OF BINDING BETWEEN PODOCIN AND KERATIN 8 FOR USE IN THE TREATMENT OF NEPHROTIC SYNDROME | May 2022 | March 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17755084 | Schizophrenic Disorder Treatment using Combination Therapy | April 2022 | September 2025 | Allow | 41 | 1 | 0 | No | No |
| 17768130 | Combination Therapy for Treating a Hematological Malignancy | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17768113 | Improved Topical Composition of Colchicine | April 2022 | September 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17713384 | Osteogenic agents and uses thereof | April 2022 | April 2025 | Allow | 36 | 3 | 1 | No | No |
| 17766081 | PHARMACOLOGICAL COMPOSITION FOR TREATING PROCTOLOGICAL DISEASES (VARIANTS) | April 2022 | December 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17763597 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA, CONTAINING UNNATURAL AMINO ACID | March 2022 | December 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17762666 | TREATMENT COMPRISING THE USE OF FXR AGONISTS | March 2022 | September 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17683197 | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections | February 2022 | August 2024 | Allow | 30 | 2 | 0 | No | No |
| 17579271 | NEXT GENERATION REMDESIVIR ANTIVIRALS | January 2022 | June 2025 | Allow | 41 | 4 | 1 | No | No |
| 17624629 | IMIDAZOTHIAZOLE COMPOUNDS AND METHODS FOR TREATING PLANT NEMATODE INFECTIONS | January 2022 | November 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17608950 | EZH2 INHIBITOR AND USE THEREOF | November 2021 | October 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17513383 | PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF | October 2021 | February 2023 | Abandon | 16 | 4 | 0 | No | Yes |
| 17605828 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | October 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17605456 | DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUG | October 2021 | February 2026 | Abandon | 52 | 2 | 0 | No | No |
| 17603386 | PRODRUG OF CASPASE INHIBITOR | October 2021 | September 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17602910 | STABILIZATION OF SUSPENSION CONCENTRATES BY HIGHLY SULFONATED LIGNOSULFONATE | October 2021 | February 2026 | Abandon | 52 | 2 | 0 | No | No |
| 17602028 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | October 2021 | August 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17600194 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | September 2021 | July 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17600172 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | September 2021 | October 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17593877 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17598500 | METHOD OF PROTECTING FIELD CORN FROM DAMAGE BY A PLANT PATHOGEN | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17441222 | PHARMACEUTICAL COMPOSITION FOR TREATING MACULAR DEGENERATION INCLUDING IMIDAZOLINE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | September 2021 | August 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17438841 | SPECIFICALLY SUBSTITUTED 3-(2-HALOGEN-6-ALKYL-4-PROPINYLPHENYL)-3-PYRROLIN-2-ONES AND TO THE USE THEREOF AS HERBICIDES | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17438452 | COMBINATION DRUG TREATMENT FOR HUMAN CYTOMEGALOVIRUS | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17437236 | INHIBITION OF ADENOVIRUS WITH FILOCICLOVIR | September 2021 | April 2025 | Allow | 43 | 3 | 0 | No | No |
| 17406035 | CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS | August 2021 | March 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17431470 | MULTIPHASIC CONTRACEPTIVE AND/OR HORMONE REPLACEMENT THERAPY | August 2021 | May 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17431460 | INHIBITOR OF BTK AND MUTANTS THEREOF | August 2021 | January 2026 | Allow | 53 | 2 | 1 | Yes | No |
| 17397984 | ARYL SULFIDE COMPRISING BENZYLAMINE, SYNTHESIS METHOD AND APPLICATION THEREOF | August 2021 | July 2025 | Allow | 48 | 2 | 1 | No | No |
| 17428029 | TREATMENT AND PREVENTION OF INTESTINAL INFLAMMATORY DISEASES WITH A BILE ACID DERIVATIVE | August 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17426805 | NOVEL DEVICES | July 2021 | March 2026 | Abandon | 56 | 2 | 1 | No | Yes |
| 17381857 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | July 2021 | June 2024 | Abandon | 35 | 3 | 1 | No | No |
| 17419664 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | June 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17309764 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | June 2021 | August 2025 | Allow | 50 | 2 | 1 | No | No |
| 17331366 | METHODS OF TREATING THROMBOSIS | May 2021 | March 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17331599 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | May 2021 | November 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17289816 | TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE | April 2021 | May 2025 | Abandon | 49 | 4 | 1 | No | No |
| 17258724 | USE OF COMPOUND IN DRUG FOR PREVENTING, TREATING, OR ALLEVIATING PAIN | January 2021 | November 2025 | Abandon | 59 | 5 | 1 | No | No |
| 17099531 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | November 2020 | November 2024 | Abandon | 48 | 4 | 0 | Yes | No |
| 17052192 | NOVEL HETEROCYCLE DERIVATIVE | November 2020 | October 2025 | Allow | 59 | 3 | 1 | No | No |
| 17014954 | CANNABINOID FORMULATIONS AND METHODS INCLUDING THE ANTIOXIDANT C60 | September 2020 | November 2024 | Abandon | 50 | 4 | 0 | No | No |
| 16767886 | COMPOSITIONS AND METHODS FOR CHARACTERIZING CANCER | May 2020 | November 2024 | Abandon | 54 | 4 | 0 | Yes | No |
| 16624549 | Stratification Of Acute Myeloid Leukaemia Patients For Sensitivity To Kinase Pathway Inhibitor Therapy | December 2019 | December 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16419927 | Method for activating AMPK and the use of Adenine | May 2019 | August 2025 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 16419892 | Method for activating AMPK and the use of Adenine | May 2019 | May 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16277871 | COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | February 2019 | February 2020 | Allow | 12 | 1 | 0 | No | No |
| 16309733 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | December 2018 | January 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16065441 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | June 2018 | September 2024 | Allow | 60 | 7 | 0 | Yes | Yes |
| 15732352 | Method for producing solid formulations with improved dissolution by annealing with an adjuvant | October 2017 | September 2021 | Abandon | 47 | 6 | 1 | No | No |
| 15727772 | COMPOSITIONS FOR TOPICAL TREATMENT OF MICROBIAL INFECTIONS | October 2017 | September 2024 | Allow | 60 | 10 | 0 | Yes | No |
| 15062499 | ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS | March 2016 | March 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 14883720 | INHIBITORS OF BETA-SECRETASE | October 2015 | November 2018 | Allow | 37 | 2 | 1 | Yes | No |
| 14792375 | Na/K-ATPase Ligand and Uses Thereof in Wound Healing | July 2015 | September 2016 | Allow | 14 | 1 | 0 | Yes | No |
| 14734999 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | June 2015 | May 2018 | Allow | 35 | 3 | 0 | Yes | Yes |
| 14342889 | PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF | March 2014 | June 2020 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 14010354 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | August 2013 | May 2015 | Allow | 21 | 1 | 0 | No | No |
| 13965499 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | August 2013 | June 2015 | Allow | 22 | 3 | 0 | Yes | No |
| 13942245 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | July 2013 | June 2015 | Allow | 23 | 3 | 0 | Yes | No |
| 13986573 | Method for treament of neurologic dysfunction | May 2013 | February 2016 | Allow | 60 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCMILLIAN, KARA RENITA.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCMILLIAN, KARA RENITA works in Art Unit 1623 and has examined 93 patent applications in our dataset. With an allowance rate of 67.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner MCMILLIAN, KARA RENITA's allowance rate of 67.7% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MCMILLIAN, KARA RENITA receive 2.81 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MCMILLIAN, KARA RENITA is 47 months. This places the examiner in the 8% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.6% benefit to allowance rate for applications examined by MCMILLIAN, KARA RENITA. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.5% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 27% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 38.0% are granted (fully or in part). This grant rate is in the 26% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 4.3% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.